Candel Therapeutics, Inc.
CADL Nasdaq
SEC CIK 1841387
Follow Candel Therapeutics
Weekly email: filings, results
Net income
−$21.9M
−94.1% vs same quarter last year
EPS, diluted
−$0.28
−33.3% vs same quarter last year
Operating cash flow
−$23.1M
−125.9% vs same quarter last year
Operating income
−$23M
−74% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$38.2M |
| FY24 | - | −$55.2M |
| FY23 | - | −$37.9M |
| FY22 | $125K | −$18.8M |
| FY21 | $125K | −$36.1M |
| FY20 | $125K | −$17.7M |
| FY19 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | - | - |
| FY23 | - | - |
| FY22 | −27777.6% | −15035.2% |
| FY21 | −20580.8% | −28899.2% |
| FY20 | −11048% | −14144% |
| FY19 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$38.9M |
| FY24 | −$27M |
| FY23 | −$34.7M |
| FY22 | −$32.7M |
| FY21 | −$24.1M |
| FY20 | −$10.5M |
| FY19 | - |
- Candel Therapeutics
- Healthcare median
Show the numbers
| Year | Candel Therapeutics | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | −15035.2% | −80.4% |
| FY21 | −28899.2% | −71.8% |
| FY20 | −14144% | −62.2% |
| FY19 | - | −46.2% |